BACKGROUND: Pseudoxanthoma elasticum (PXE) is an autosomal recessive disease caused by loss-of-function mutations in ABCC6 and characterized by elastic calcification leading to dermal, ocular, and ischemic vascular disease. We tested the hypothesis that heterozygosity for R1141X, the most frequent PXE-causing mutation in Caucasians, associated with risk of ischemic vascular disease, as previous studies suggested 4- to 11-fold risk of ischemic heart disease (IHD) in heterozygotes. METHODS AND RESULTS: We studied 10,276 persons from the general population, including 1985 with IHD and 989 with ischemic cerebrovascular disease (ICVD). We examined 45,603 individuals from a cross-sectional general population study, of whom 3738 had IHD and 2335 had ICVD. Finally, we compared 4851 patients with IHD and 625 patients with ICVD with, respectively, 4851 and 625 matched control subjects. We genotyped participants in all studies for ABCC6 R1141X. The frequency of R1141X was 0.6% in all populations studied. ABCC6 R1141X genotype was not associated with an increased risk of IHD, myocardial infarction, ICVD, or ischemic stroke. Furthermore, R1141X genotype did not interact with age on risk of the largest end point, IHD. Finally, R1141X genotype did not associate with variation in plasma levels of high-sensitivity C-reactive protein, fibrinogen, blood pressure, or lipid and lipoproteins in the general population. CONCLUSIONS: In 4 studies including 66 831 participants and 13 642 cases with ischemic vascular events, heterozygosity for ABCC6 R1141X did not associate with risk of IHD, myocardial infarction, ICVD, or ischemic stroke.
BACKGROUND: Pseudoxanthoma elasticum (PXE) is an autosomal recessive disease caused by loss-of-function mutations in ABCC6 and characterized by elastic calcification leading to dermal, ocular, and ischemic vascular disease. We tested the hypothesis that heterozygosity for R1141X, the most frequent PXE-causing mutation in Caucasians, associated with risk of ischemic vascular disease, as previous studies suggested 4- to 11-fold risk of ischemic heart disease (IHD) in heterozygotes. METHODS AND RESULTS: We studied 10,276 persons from the general population, including 1985 with IHD and 989 with ischemic cerebrovascular disease (ICVD). We examined 45,603 individuals from a cross-sectional general population study, of whom 3738 had IHD and 2335 had ICVD. Finally, we compared 4851 patients with IHD and 625 patients with ICVD with, respectively, 4851 and 625 matched control subjects. We genotyped participants in all studies for ABCC6R1141X. The frequency of R1141X was 0.6% in all populations studied. ABCC6R1141X genotype was not associated with an increased risk of IHD, myocardial infarction, ICVD, or ischemic stroke. Furthermore, R1141X genotype did not interact with age on risk of the largest end point, IHD. Finally, R1141X genotype did not associate with variation in plasma levels of high-sensitivity C-reactive protein, fibrinogen, blood pressure, or lipid and lipoproteins in the general population. CONCLUSIONS: In 4 studies including 66 831 participants and 13 642 cases with ischemic vascular events, heterozygosity for ABCC6R1141X did not associate with risk of IHD, myocardial infarction, ICVD, or ischemic stroke.
Authors: Christopher Brampton; Zouhair Aherrahrou; Li-Hsieh Chen; Ludovic Martin; Arthur A B Bergen; Theo G M F Gorgels; Jeannette Erdmann; Jeannette Erdfdi; Heribert Schunkert; Zalán Szabó; András Váradi; Olivier Le Saux Journal: Am J Pathol Date: 2014-01 Impact factor: 4.307
Authors: Georges Lefthériotis; Loukman Omarjee; Olivier Le Saux; Daniel Henrion; Pierre Abraham; Fabrice Prunier; Serge Willoteaux; Ludovic Martin Journal: Front Genet Date: 2013-02-12 Impact factor: 4.599
Authors: Olivier Le Saux; Ludovic Martin; Zouhair Aherrahrou; Georges Leftheriotis; András Váradi; Christopher N Brampton Journal: Front Genet Date: 2012-12-12 Impact factor: 4.599
Authors: Fabrice Prunier; Gwenola Terrien; Yannick Le Corre; Ailea L Y Apana; Loïc Bière; Gilles Kauffenstein; Alain Furber; Arthur A B Bergen; Theo G M F Gorgels; Olivier Le Saux; Georges Leftheriotis; Ludovic Martin Journal: PLoS One Date: 2013-07-23 Impact factor: 3.240